November 15, 2013 08:36 ET

WallStreetCorner.Com Makes NovaBay Its Stock Pick in November

Veteran Investment Writer Larry Oakley Calls NovaBay "a Value Play"

NEW YORK, NY--(Marketwired - Nov 15, 2013) - Larry Oakley, founder of, selected NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) as his featured stock pick [] on November 12, 2013. NovaBay is a clinical stage biopharmaceutical company developing non-antibiotic anti-microbial products.

"I strongly suggest that you seriously look into adding it to your portfolio of high future profit investments," Oakley wrote.

Oakley argued that NovaBay has been underappreciated as an investment. Despite its recent setback in impetigo, the company has been making great progress in other business units, he explained. Its FDA-approved skin and wound cleanser, NeutroPhase®, has been used successfully to manage life-threatening wounds of patients. And NovaBay recently announced positive top-line results from its phase 2 clinical study for auriclosene-based irrigation solution to prevent the encrustation and blockage of long-term indwelling catheters.

But brokers and investors have failed to take this progress into account, he said. As a result, the gap between the mistaken perception of Nova Bay and the reality of a company with bright prospects has created a buying opportunity, Oakley argued. "Here's a Value Play if I've ever seen one," he wrote. "Investment sources I've spoken to believe that NBY has recently been oversold & is a true value investment play."

Oakley also featured NovaBay in the 7/25/2013 issue of his newsletter, the Conservative Speculator.

Contact: You may contact Larry Oakley by email:, or call him at his private office number 843-645-2729 - he has put aside the time from 1:45 p.m. to 2:45 p.m. Eastern to chat with his readers. 

About CEONews.Tv:
CEONews.Tv is an online market news and mobile news provider that brings investors -- Big News For The SmallCap Market!™. CEONews.Tv offers platforms that allow CEOs, CFOs, COOs, Presidents and Directors of companies to deliver answers to the questions that investors would like asked. Through these mediums Executives share their insights, accomplishments, current projects, daily challenges they face and the future goals and aspirations they have for the companies that they lead. For further information please visit To have Your Company Interviewed please send an email request to: or call 765.CEO.NEWS (236-6397).

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions relating to NovaBay's future business prospects and clinical trials. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. In addition, description of anyone's past success, either financial or strategic, is not a guarantee of future success. This news release speaks as of the date first set forth above and neither CEONews.Tv or the interviewed company assumes any responsibility to update the information included herein for events occurring after the date hereof.

Contact Information